Sarlósejtes vérszegénység: vizsgálatok itt: Németország
10 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Berlin, Essen, Stuttgart
- Életkor
- 10 év to 65 év
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - 2. fázisBefejeződöttSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Where
- Freiburg im Breisgau
- Életkor
- 12 év and over
- People
- 70 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06699849 · EU 2024-513440-29-00 - 3. fázisTaking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Berlin, Freiburg im Breisgau
- Életkor
- 2 év and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - 2/3. fázisTaking peopleA Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Where
- Aachen, Duesseldorf, Stuttgart
- Életkor
- 12 év to 64 év
- People
- 389 worldwide
- Run by
- Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00 - 3. fázisTaking peopleA Long-term Follow-up Study in Participants Who Received CTX001
- Where
- Duesseldorf, Regensburg, Tuebingen
- Életkor
- 2 év to 64 év
- People
- 160 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00 - 4. fázisFut, nem toborozRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- Where
- Heidelberg
- Életkor
- 6 hónap to 100 év
- People
- 130 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00 - 3. fázisTaking peopleEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- Where
- Duesseldorf
- Életkor
- 12 év to 35 év
- People
- 26 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT05477563 · EU 2024-514641-12-00 - No phaseTaking peoplePASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
- Where
- Hamburg, Heidelberg
- Életkor
- 9 hónap to 23 hónap
- People
- 180 worldwide
- Run by
- Nova Laboratories Limited
See details and how to joinNCT06923111 - No phaseTaking peopleSickle-cell Disease Registry of the GPOH
- Where
- Heidelberg
- Életkor
- 0 év to 100 év
- People
- 1000
- Run by
- University Hospital Heidelberg
See details and how to joinNCT03327428 - 2. fázisTaking peopleA Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD
- Where
- Aachen, Berlin, Düsseldorf, Frankfurt, Heidelberg, Regensburg, Tübingen, Würzburg
- Életkor
- 2 év to 35 év
- People
- 212 worldwide
- Run by
- University of Regensburg
See details and how to joinNCT04201210